Compare ONL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | VTGN |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 28.8M |
| IPO Year | N/A | N/A |
| Metric | ONL | VTGN |
|---|---|---|
| Price | $2.26 | $0.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 308.1K | ★ 5.8M |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.46 | $0.68 |
| 52 Week High | $4.25 | $5.14 |
| Indicator | ONL | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 22.84 |
| Support Level | $1.97 | $0.68 |
| Resistance Level | $2.28 | $0.84 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.04 | -0.35 |
| Stochastic Oscillator | 93.06 | 1.16 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.